Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, for ISIS Pharmaceuticals, Inc. (now Ionis Pharmaceuticals). The company is a biopharmaceutical firm focused on the discovery and development of antisense drugs. As of the reporting date, the company had 47,087,796 shares of common stock outstanding. The company remains in a development phase, relying heavily on collaborative agreements, research grants, and interest income to fund operations, and has not yet achieved profitability.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 | As of Sep 30, 2001 |
|---|---|---|---|
| Total Revenue | $19.3 million | $31.5 million | - |
| Net Loss | $(12.3) million | $(58.2) million | - |
| Net Loss Applicable to Common Stock | $(12.6) million | $(59.2) million | - |
| Diluted Net Loss Per Share | $(0.29) | $(1.43) | - |
| Cash and Cash Equivalents | - | - | $12.3 million |
| Short-term Investments | - | - | $200.9 million |
| Total Current Assets | - | - | $220.3 million |
| Total Current Liabilities | - | - | $36.4 million |
| Working Capital | - | - | $183.9 million |
| Long-term Obligations | - | - | $123.7 million |
| Operating Cash Flow (9 months) | - | $4.8 million | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the nine months ended September 30, 2001, increased to $31.5 million from $29.3 million in the prior year period. This was driven primarily by a new licensing agreement with Eli Lilly and Company for the drug ISIS 3521, as well as collaborations with Merck and Celera. Notably, the prior year included a one-time $10.8 million patent sale to Coley Pharmaceutical Group, which was not repeated in 2001.
- Expense Increases: Research and development (R&D) expenses rose significantly to $59.0 million for the nine months ended September 30, 2001, compared to $42.0 million in 2000. This increase reflects the advancement of twelve products in development (up from seven in 2000), including more expensive Phase III clinical trials.
- Stock-Based Compensation: Compensation related to stock options increased to $3.1 million for the nine-month period in 2001 from $0.6 million in 2000, largely due to an option exchange program and variable accounting for stock price fluctuations.
- Interest Expense: Interest expense increased to $11.1 million for the nine months ended September 30, 2001, from $9.6 million in 2000, due to increased debt from Elan Corporation and imputed interest on a new loan from Lilly.
- Liquidity Position: Cash, cash equivalents, and short-term investments increased to $213.2 million from $127.3 million at year-end 2000. This improvement was fueled by a $75 million equity investment from Lilly, $25 million in upfront fees, and a $10 million drawdown on a Lilly loan.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management expects to continue incurring operating losses for the next several years as it advances its drug pipeline. The company believes its current cash, cash equivalents, and short-term investments, combined with contract revenue and interest income, are sufficient to fund operations for at least the next three years. On October 9, 2001, the company filed a registration statement for a potential public offering of up to 5 million shares of common stock, with estimated net proceeds of $85.7 million to $98.6 million.
Key Developments
- Eli Lilly Alliance: A strategic alliance was formed involving a $75 million equity purchase, a $25 million upfront fee for ISIS 3521, and a $100 million interest-free loan commitment.
- Clinical Progress: Phase II data for ISIS 2302 (ulcerative colitis) showed statistically significant improvements in disease activity. ISIS 3521 (lung cancer) is in Phase III trials.
- Hybridon Acquisition: The company acquired an exclusive license to Hybridon's antisense patents for $15 million in cash and $19.5 million in stock.
Risk Factors
- Regulatory Approval: Failure to obtain FDA or other regulatory approvals for drug candidates would prevent commercialization.
- Development Risks: Antisense technology is relatively new; clinical trials may fail to demonstrate safety or efficacy.
- Partner Dependence: The company relies on partners like Lilly, Merck, and Elan for funding and development. Termination of these partnerships could materially harm the business.
- Intellectual Property: The company is involved in litigation against Sequitur, Inc., alleging patent infringement. Failure to protect IP rights could impact future revenues.
- Manufacturing: Large-scale manufacturing of oligonucleotides is unproven, and supply chain limitations could hinder commercialization.
Investor Verification Checklist
- Lilly Collaboration Terms: Verify the specific milestones and contingent funding obligations within the Eli Lilly agreement to assess future revenue potential.
- Cash Burn Rate: Confirm the sustainability of the $183.9 million working capital position against the projected R&D spend for the twelve products in the pipeline.
- Debt Obligations: Review the terms of the $40 million private placement notes (accruing to $78 million by 2002) and the $100 million Lilly loan to understand future liquidity requirements.
- Patent Litigation: Monitor the outcome of the lawsuit against Sequitur, Inc., as a loss could invalidate key patents and reduce licensing revenue.
- Clinical Trial Results: Track the Phase III results for ISIS 3521 and Phase II results for ISIS 2302, as these are critical for future commercialization and partner funding.